Enterprise Value to EBITDA Ratio: Aura Biosciences, Inc. (AURA)

Aura Biosciences, Inc. (AURA) - corporate logo

The prospects for Aura Biosciences, Inc. (AURA) depend on the results of clinical trials for eye tumor treatments and regulatory approvals. The market value dynamics of the asset, which stand at 0.00, confirm the potential of the strategy to capture an untapped niche through the implementation of innovative viral conjugates. High research expenditures and stringent patent protection create a powerful defensive barrier, precluding the emergence of competing analogs.

AURA Aura Biosciences Inc: Business Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/18/2026

Metric breakdowns and analytics for Aura Bio (AURA)

- current price and projected stock value:
- company stock exchange capitalization indicators:
Fundamental company analysis:AURA (Aura Biosciences, Inc.)
Product sample of Aura Biosciences Inc

The resilience of Aura Biosciences, Inc. (AURA) is based on exclusive targeted therapy technologies for eye cancer. Analyzing the business valuation via the EV/EBITDA multiple, an investor sees the ratio of the company's total enterprise value to its operating profit before depreciation and amortization. This metric neutralizes the impact of debt load and tax regimes, stripping the financial result. A decrease in this indicator signals that assets are undervalued relative to their ability to generate cash flow.

Key competitors

BeiGene Oncology - Enterprise Value to EBITDA Ratio|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology Corp (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen - Business Value to Operating Income Before Depreciation|BCAX (Bicara Therapeutics Inc) - EV/EBITDA Multiple|Company Value to EBITDA personalis.com PSNL|EV/EBITDA Multiple ERAS|Delcath Systems - Enterprise Value to Operating Income Before Depreciation|Y-mAbs Therapeutics Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Candel Therapeutics CADL|accuray.com - EV/EBITDA Multiple|SLS: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACTU (actuatetherapeutics.com) - Enterprise Value to EBITDA Ratio|CTOR - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization tuhurabio.com|EV/EBITDA Multiple Protara Tx|Enterprise Value to EBITDA Ratio FATE (Fate Therapeutics Corp)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization WHWK (Aadi Bioscience)|TScan Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Champions Oncology (CSBR) - Company Value to EBITDA|XBiotech - EV/EBITDA Multiple|CEL-SCI (CVM) - Enterprise Value to EBITDA Ratio|OS Therapies Inc (OSTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|radiopharmtheranostics.com - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Artiva Biotherapeutics Inc.|Company Value to EBITDA Adlai Nortye Ltd. ANL|EV/EBITDA Multiple VERU|TPST - Company Value to EBITDA|EV/EBITDA Multiple XLO (Xilio Therapeutics)|RENB - Enterprise Value to EBITDA Ratio|muraloncology.com - EV/EBITDA Multiple|KAPA - EV/EBITDA Multiple|OKUR: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio GDTC (CytoMed Therapeutics Ltd)|CRIS (curis.com) - EV/EBITDA Multiple|Apollomics, Inc. (APLM) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio THAR (Tharimmune, Inc.)|ADVB (Advanced Biomed) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple GNPX (Genprex Inc)|calidibio.com (CLDI) - Company Value to EBITDA|sunshinebiopharma.com - EV/EBITDA Multiple|Company Value to EBITDA Xenetic Biosciences, Inc.|SLRX (Salarius Pharmaceuticals) - Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Ratio Purple Biotech Ltd.|AONC (American Oncology Network Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio BeOne Medicines (BGNE)|EV/EBITDA Multiple CKPT|ELEV - Company Value to EBITDA|iCAD Inc. - Enterprise Value to EBITDA Ratio|IKNA: Enterprise Value to Operating Income Before Depreciation|Notable Labs Ltd - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation VIRX (Viracta Therapeutics Inc.)|MorphoSys AG (MOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio NAYA Biosciences|AAPGV (ascentage.com) - EV/EBITDA Multiple